HC Wainwright Issues Positive Estimate for CLSD Earnings

Clearside Biomedical, Inc. (NASDAQ:CLSD) – Investment analysts at HC Wainwright increased their Q1 2025 earnings estimates for shares of Clearside Biomedical in a note issued to investors on Monday, March 31st. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.12) for the quarter, up from their previous estimate of ($0.13). HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Clearside Biomedical’s current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Clearside Biomedical’s Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.45) EPS.

Clearside Biomedical (NASDAQ:CLSD) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.03. The business had revenue of $0.31 million during the quarter, compared to analysts’ expectations of $0.27 million.

Several other research analysts also recently issued reports on the company. Needham & Company LLC cut their price target on Clearside Biomedical from $6.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, March 28th. StockNews.com cut Clearside Biomedical from a “hold” rating to a “sell” rating in a report on Tuesday, March 18th. Finally, Chardan Capital reissued a “buy” rating and issued a $6.00 price target on shares of Clearside Biomedical in a report on Friday, March 28th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $5.25.

Clearside Biomedical Price Performance

Shares of CLSD stock opened at $0.93 on Thursday. Clearside Biomedical has a 1-year low of $0.77 and a 1-year high of $1.65. The business’s fifty day moving average price is $0.96 and its 200 day moving average price is $1.04. The firm has a market capitalization of $71.74 million, a PE ratio of -2.07 and a beta of 2.03.

Institutional Investors Weigh In On Clearside Biomedical

Several institutional investors and hedge funds have recently bought and sold shares of CLSD. Geode Capital Management LLC increased its holdings in shares of Clearside Biomedical by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 764,058 shares of the company’s stock valued at $726,000 after purchasing an additional 32,672 shares during the period. Northern Trust Corp grew its position in Clearside Biomedical by 24.0% in the 4th quarter. Northern Trust Corp now owns 165,499 shares of the company’s stock valued at $157,000 after buying an additional 32,048 shares in the last quarter. Finally, Investor s Fiduciary Advisor Network LLC acquired a new position in Clearside Biomedical during the 4th quarter valued at about $32,000. Institutional investors and hedge funds own 18.75% of the company’s stock.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.